LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

Search

Simulations Plus Inc

Slēgts

SektorsVeselības aprūpe

12.04 -1.79

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

11.72

Max

12.27

Galvenie mērījumi

By Trading Economics

Ienākumi

1.4M

676K

Pārdošana

961K

18M

P/E

Sektora vidējais

48.528

121.746

EPS

-0.034

Dividenžu ienesīgums

0.48

Peļņas marža

3.67

Darbinieki

212

EBITDA

-3M

2.3M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+54.6% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

0.48%

2.26%

Nākamie ieņēmumi

2026. g. 2. apr.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-120M

248M

Iepriekšējā atvēršanas cena

13.83

Iepriekšējā slēgšanas cena

12.04

Ziņu noskaņojums

By Acuity

30%

70%

85 / 351 Rangs Healthcare

Simulations Plus Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 17. febr. 23:44 UTC

Karstas akcijas

Stocks to Watch: La-Z-Boy, Palo Alto Networks, Caesars

2026. g. 17. febr. 23:20 UTC

Peļņas

Palo Alto Networks Lifts FY26 Revenue Outlook as 2Q Profit Jumps -- Update

2026. g. 17. febr. 22:57 UTC

Peļņas

Santos Fiscal Year Net Profit Falls 33%, Nears Start of Alaska Project

2026. g. 17. febr. 21:59 UTC

Peļņas

Palo Alto Networks Lifts FY26 Revenue Outlook as 2Q Profit Jumps

2026. g. 17. febr. 23:54 UTC

Tirgus saruna

Nikkei May Rise as Fears About AI Disruption Ease -- Market Talk

2026. g. 17. febr. 23:54 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 17. febr. 23:54 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 17. febr. 23:45 UTC

Tirgus saruna

Suncorp's Outperformance of IAG Could Be Hard to Sustain -- Market Talk

2026. g. 17. febr. 23:19 UTC

Peļņas

Palo Alto's Guidance Overshadows Strong Earnings. Its Stock Is Down. -- Barrons.com

2026. g. 17. febr. 23:15 UTC

Peļņas

Palo Alto's Guidance Overshadows Strong Earnings. Its Stock Is Down. -- Barrons.com

2026. g. 17. febr. 22:58 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Netflix Would Operate Warner's Studios, HBO Largely the Same -- Market Talk

2026. g. 17. febr. 22:58 UTC

Iegādes, apvienošanās, pārņemšana

BlueScope Steel: Board Committed to Optimizing Value For Shareholders

2026. g. 17. febr. 22:57 UTC

Iegādes, apvienošanās, pārņemšana

BlueScope Steel to Consider Revised SGH, Steel Dynamics Takeover Bid

2026. g. 17. febr. 22:50 UTC

Iegādes, apvienošanās, pārņemšana

Agnico-Eagle Mines Acquired 662,780 Common Shrs of Maple Gold Mines at C$2.45 Per Common Shr >AEM.T

2026. g. 17. febr. 22:44 UTC

Peļņas

Palo Alto Reports Strong Earnings. Its Stock Is Down. -- Barrons.com

2026. g. 17. febr. 22:42 UTC

Peļņas

Santos FY Net Profit Falls 33%, Nears Start of Alaska Project

2026. g. 17. febr. 22:36 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Netflix Sarandos: Paramount Causing Confusion Around Warner Deal -- Market Talk

2026. g. 17. febr. 22:36 UTC

Peļņas

Santos Final Dividend 10.3 U.S. Cents/Security

2026. g. 17. febr. 22:36 UTC

Peļņas

Santos FY Underlying Profit US$898 Million, Down 25%

2026. g. 17. febr. 22:35 UTC

Peļņas

Santos FY Revenue US$4.94 Billion, Down 8%

2026. g. 17. febr. 22:35 UTC

Peļņas

Correct: Santos FY Net Profit US$818 Million, Down 33%

2026. g. 17. febr. 22:35 UTC

Iegādes, apvienošanās, pārņemšana

Berkshire Buys New York Times Stock; Sells Apple, Bank of America, Amazon In 4Q -- Barrons.com

2026. g. 17. febr. 22:34 UTC

Peļņas

Santos FY Net Profit US$818 Billion, Down 33%

2026. g. 17. febr. 22:02 UTC

Iegādes, apvienošanās, pārņemšana

Berkshire Pares Stakes in Apple and BofA, Adds New York Times Position -- Update

2026. g. 17. febr. 21:50 UTC

Iegādes, apvienošanās, pārņemšana

Steel Dynamics: SGH Would Buy BlueScope, On-sell North American Operations to SDI, As Earlier Proposed

2026. g. 17. febr. 21:50 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Tech, Media & Telecom Roundup: Market Talk

2026. g. 17. febr. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 17. febr. 21:49 UTC

Iegādes, apvienošanās, pārņemšana

Steel Dynamics Says Revised Proposal Continues to Present Highly Strategic Opportunity For SDI Shareholders

2026. g. 17. febr. 21:48 UTC

Iegādes, apvienošanās, pārņemšana

Steel Dynamics: BlueScope Offer a 56% Premium to 52-Week Volume Weighted Average Price

2026. g. 17. febr. 21:48 UTC

Iegādes, apvienošanās, pārņemšana

Steel Dynamics: Consideration To Be Comprised Entirely of Cash

Salīdzinājums

Cenas izmaiņa

Simulations Plus Inc Prognoze

Cenas mērķis

By TipRanks

54.6% augšup

Prognoze 12 mēnešiem

Vidējais 19 USD  54.6%

Augstākais 19 USD

Zemākais 19 USD

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Simulations Plus Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

4 ratings

2

Pirkt

2

Turēt

0

Pārdot

Noskaņojums

By Acuity

85 / 351 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat